Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

NK Cells in Cord Blood Transplantation

Phase 1

Conditions: Acute Lymphoblastic Leukemia in Remission
Myelodysplastic Syndrome
Recurrent Acute Lymphoblastic Leukemia
Recurrent Non-Hodgkin Lymphoma
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
DS Stage III Plasma Cell Myeloma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
ISS Stage III Plasma Cell Myeloma
Acute Biphenotypic Leukemia
Recurrent Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Melphalan
Drug: Mycophenolate Mofetil
Biological: Natural Killer Cell Therapy
Biological: Rituximab
Drug: Tacrolimus
Procedure: Umbilical Cord Blood Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2012-06-14

Last Posted Date: 2020-02-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT01619761

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Not Applicable

Terminated

Conditions: Acute Leukemia
Chronic Leukemia
Myelodysplastic Syndrome
Non-Hodgkins Lymphoma

Interventions: Radiation: total-body irradiation (TBI)
Drug: thiotepa
Drug: fludarabine phosphate
Drug: melphalan
Biological: anti-thymocyte globulin
Procedure: allogeneic hematopoietic stem cell transplantation
Biological: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2012-05-15

Last Posted Date: 2018-08-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT01598025

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Phase 2

Terminated

Conditions: Myeloid Malignancy
Bone Marrow Failure Syndrome
Severe Immune Dysregulation
Metabolic Disease
Transfusion-dependent Red Blood Cell (RBC) Defect
Congenital Immunodeficiency

Interventions: Drug: Busulfan
Drug: Alemtuzumab
Drug: Fludarabine
Drug: Clofarabine

First Posted Date: 2012-05-11

Last Posted Date: 2020-02-26

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 16

Registration Number: NCT01596699

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Randomised Trial in Waldenstrom's Macroglobulinaemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinaemia

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide
Biological: Rituximab
Drug: Fludarabine

First Posted Date: 2012-05-07

Last Posted Date: 2021-06-18

Lead Sponsor: University College, London

Target Recruit Count: 60

Registration Number: NCT01592981

Locations: 🇬🇧
University College Hospital, London, United Kingdom
🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧
Maidstone Hospital, Maidstone, United Kingdom

and more 27 locations

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Phase 1

Terminated

Conditions: Melanoma
Metastatic Cancer

Interventions: Drug: Vemurafenib
Biological: Young TIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin

First Posted Date: 2012-04-25

Last Posted Date: 2019-11-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT01585415

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

Phase 2

Completed

Conditions: Cervical Cancer
Vaginal Cancer
Anal Cancer
Penile Cancer
Oropharyngeal Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Young TIL
Drug: Aldesleukin

First Posted Date: 2012-04-25

Last Posted Date: 2018-03-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT01585428

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer
Ovarian Cancer
Lung Cancer
Cervical Cancer
Mesothelioma

Interventions: Drug: Fludarabine
Biological: Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)
Drug: Cyclophosphamide
Drug: Aldesleukin

First Posted Date: 2012-04-24

Last Posted Date: 2019-10-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT01583686

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Crohn's Allogeneic Transplant Study

Phase 2

Terminated

Conditions: Crohn Disease

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Drug: Mycophenolic Acid
Other: Quality-of-Life Assessment
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2012-04-04

Last Posted Date: 2020-02-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01570348

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Phase 2

Terminated

Conditions: Stage I Multiple Myeloma
Stage III Multiple Myeloma
Refractory Multiple Myeloma
Stage II Multiple Myeloma

Interventions: Other: pharmacological study
Drug: tacrolimus
Drug: sirolimus
Biological: anti-thymocyte globulin
Drug: fludarabine phosphate
Drug: busulfan
Drug: bortezomib
Procedure: allogeneic hematopoietic stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2012-02-16

Last Posted Date: 2017-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01534143

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia in Remission
Childhood Acute Myeloid Leukemia in Remission
Childhood Chronic Myelogenous Leukemia
Childhood Grade III Lymphomatoid Granulomatosis
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Drug: tacrolimus
Drug: mycophenolate mofetil
Drug: methotrexate
Other: laboratory biomarker analysis
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2012-02-09

Last Posted Date: 2019-09-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 94

Registration Number: NCT01529827

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy